Shares in SteadyMed (NSDQ:STDY) rose yesterday after the pharmaceutical company reported its 4th quarter results. The San Ramon, Calif.-based company posted losses of -$2.4 million, or -12¢ per share, on sales of $400,000 for the 3 months ended Dec. 31, for bottom-line growth of 63.1% on sales loss of -25.6% compared with the same period last year. […]
SteadyMed Therapeutics
SteadyMed details commercialization plans for Trevyent
SteadyMed Therapeutics (NSDQ:STDY) today detailed the development of its lead drug candidate, Trevyent (treprostinil sodium), for the treatment of pulmonary arterial hypertension using its PatchPump tech at the Parenteral Drug Assn. Conference in Huntington Beach, Calif. PatchPump is the 1st single-use, wearable, pre-filled pump and treprostinil will be the 1st drug integrated with the delivery system, according to the San […]
Patent office to review United Therapeutics, SteadyMed patent conflict
SteadyMed Therapeutics (NASDAQ:STDY) said today it that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office initiated an inter partes review against a United Therapeutics patent. The patent in question, No. 8,497,393, is related to a process to purify prostacyclin derivatives, such as treprostinil, which is used in United Therapeutics’ Remodulin and […]
SteadyMed still steady on Q2
SteadyMed Therapeutics (NASDAQ:STDY) yesterday released quarterly earnings that missed expectations and reported growing losses, but shares stayed steady. SteadyMed is a developer of hypertension and pain treatments given with a discrete, patented drug-delivery device called the PatchPump. The company is focusing on development and approval of Treyvant, a drug to treat pulmonary arterial hypertension. SteadyMed reported losses of […]
SteadyMed sets terms for $55m IPO
SteadyMed Therapeutics yesterday set the terms for its pending debut on the public market, saying it plans to float 4.25 million shares at $12 to $14 apiece.
